Democrats Cite Trump Pharma Stock Surge Tied To Medicare Exemption Law
On Friday, October 16, 2026, the Democratic minority of the Joint Economic Committee released a report saying President Trump sharply increased investments in drugmakers that got an expanded Medicare exemption.[1]
The report says Trump's pharma holdings rose from a reported $1.7 million in 2024 to as much as $56.2 million by the end of 2025, including up to $39.1 million in firms that benefited.[1] It says the portfolio bought as much as $2.55 million in shares on three dates before Trump signed the bill in July 2025, including up to $950,000 on July 1, 2025.[1] The report also says Trump's portfolio bought as much as $1 million of AbbVie stock in August 2025 after the law took effect.[1] Democrats estimate Medicare beneficiaries using cancer drugs Keytruda and Opdivo could pay roughly $5,000 more per year without negotiated prices.[1]
The changes were part of Republicans' 2025 tax and spending law, which expanded an orphan-drug exclusion to Medicare price negotiations and took effect in July 2025.[1] Democrats say that expansion concentrated gains in the stocks of affected companies, creating a conflict between policy outcomes and the president's financial interests.[1]
A White House spokesperson said the president's portfolio is independently managed and denied that Mr. Trump or his family could influence the trades.[1]
Show source details & analysis (1 source)
📌 Key Facts
- On Friday, October 16, 2026, the Joint Economic Committee’s Democratic minority released a report on President Trump’s pharmaceutical investments.
- The report finds Trump’s pharma stock holdings rose from a maximum reported $1.7 million in 2024 to as much as $56.2 million by the end of 2025.
- Up to $39.1 million of that total was in companies benefiting from an expanded orphan-drug exclusion to Medicare price negotiations in Republicans’ 2025 tax and spending law.
- The report says Trump’s portfolio bought as much as $2.55 million in shares of benefiting firms on three dates before he signed the bill in July 2025, including up to $950,000 on July 1, 2025, the day the Senate passed it.
- Trump’s portfolio also bought as much as $1 million in AbbVie stock in August 2025, after the law took effect.
- Democrats estimate Medicare beneficiaries on cancer drugs Keytruda and Opdivo could pay roughly $5,000 more per year without negotiated prices.
- A White House spokesperson says Trump’s portfolio is independently managed and denies any ability by the president or his family to influence trades.
📰 Source Timeline (1)
Follow how coverage of this story developed over time